On Jul 17, J&J (JNJ) announced strong second-quarter results, beating estimates for both earnings and sales. While the Innovative Medicines segment outperformed expectations, MedTech's performance was a bit softer than expected due to macroeconomic issues in China, increased competitive pressure and currency headwinds.Sales of J&J’s Innovative Medicines segment rose 5.5% year over year. Higher sales of key products such as Darzalex, Stelara, Tremfya, Uptravi and Erleada drove the segment’s growth. New drugs ...

Kohei Hara/DigitalVision via Getty ImagesSince my last article, Johnson & Johnson's stock price (NYSE:JNJ) has been trading sideways until July 10, mainly due to caution from financial market participants about the impact of the talcum-powder litigation on its financial position. On the other hand, the company reported Q2 2024 financial results on July 17 that beat my expectations as well as Wall Street's. It also pleased investors with the progress in developing its portfolio of FDA-approved medicines ...

CHINA - 2023/02/15: In this photo illustration, the American multinational medical devices and ... [+] pharmaceutical company Johnson & Johnson (J&J) logo is seen displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company repo ...

Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO® TITUSVILLE, N.J., July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA ...

Loading...Loading...Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China. They expect the third quarter to follow typical seasonal patterns without backlog issues, with robust MedTech markets projected for 2024 and beyond.Johnson & Johnson maintains its consistent M&A strategy, affirming continuity even after acquiring Shockwave Medic ...

Dividend stocks pay dividends to their shareholders, representing a portion of the company’s profits. Not all companies offer dividends. But those that do allow their board of directors to decide the amount based on the company’s financial health and economic considerations.Dividends are typically paid out in cash on a monthly, quarterly or yearly basis. In the U.S, the vast majority of companies pay dividends on a quarterly basis. To be eligible for a dividend, an individual must be a shareholder of record ...

Loading...Loading...Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.The company posted adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70. The pharma giant reported sales of $22.45 billion, up 4.3% year-over-year, beating the consensus of $22.31 billion, according to data from Benzinga Pro."With a robust pipeline, upcoming regulatory milestones for RYBREVANT and TREMFYA, the integration of Shockwave, and continued expansion of newly launch ...

Second-quarter results suggest the spinoff of the company's slow-growing consumer goods segment is having the intended effect.On July 17, Johnson & Johnson (JNJ 3.69%) announced second-quarter results that gave investors a lot to look forward to. Integration of newly acquired medical technology plus upcoming expansions of patent-protected medicines will help push the healthcare conglomerate's needle forward for years to come.Johnson & Johnson is made of many pieces that aren't moving in the same direction. ...

The company did a fine job of boosting sales of numerous drugs.A double beat in its latest quarter made Johnson & Johnson (JNJ 3.69%) stock a popular item on Wednesday. The encouraging (if not spectacular) results pushed the storied healthcare company's share price up by almost 4%, which contrasted positively with the 1.4% slide of the S&P 500 index on the day.Solid growth, particularly in the No. 1 categoryJohnson & Johnson revealed that its second-quarter sales came in at slightly over $22.4 billion, repr ...

Johnson & Johnson's (J&J) MedTech arm displayed resilience in its second quarter, navigating inflationary headwinds while prioritizing innovation. The unit, a key driver for J&J, remains committed to full-year growth targets despite temporary setbacks in its vision care business. Challenges arose from distributor adjustments in the contact lens market, leading to destocking. J&J officials expressed confidence in a swift recovery fueled by its innovation pipeline. This focus on innovative solutions propelled ...